Pancreatic Neoplasms Clinical Trial
Official title:
Early (4 Days) Versus Standard Drainage Removal of the Abdominal Cavity After Pancreaticoduodenectomy- - A Randomized Multicenter Study
Around two thousand pancreaticoduodenectomy (PD) are performed each year in France. This
intervention is associated with a high rate of postoperative complications including:
- pancreatic fistulas (PF);
- surgical site infections (intra-abdominal abscess, wound infection);
- delayed gastric emptying (gastroparesis);
- and hemorrhage.
The incidence of SSI (superficial and deep) is about 35% and seems influenced by the
prolonged intra-abdominal drainage. For several years, there has been a global trend to
reduce the use of abdominal drainage after abdominal surgery. Several randomized clinical
trials have shown that prophylactic drainage does not decrease the incidence of
postoperative complications during elective hepatectomy, colectomy, and cholecystectomy and
could increase the number of SSI. However, the role of prophylactic drainage after PD is so
far unclear.
The aim of this prospective randomized multicenter study is to evaluate the influence of
early (4 days) versus standard (10 to 15 days, depending on the staff clinical practice)
drainage removal of the abdominal cavity after PD, on the rate of SSI.
Materials and Methods: The technique of PD is left at the discretion of the operator as well
as the prescription of analogues of somatostatin. Drainage of the abdominal cavity is made
of one or two round silicone close suction drains or open multichannel silicone drains
placed in the vicinity of the pancreatic and biliary anastomosis. Shall be excluded patients
operated on for chronic pancreatitis and patients who underwent preoperative radiotherapy.
The 3rd postoperative day, a fistula is sought clinically, biologically and on CT-scanner
images. In case of pancreatic fistula, the patient is excluded from randomization and
drainage of the abdominal cavity is left in place depending on the different teams'
practice. Patients without fistula are randomized to either drainage removal 4 days after
surgery (D4) or standard drainage.
Introduction. Two thousand pancreaticoduodenectomy (PD) are performed per year in France
(observatory pancreatectomy GCB 2005). This intervention is associated with a high rate of
postoperative complications including pancreatic fistula (PF), the site infections (SSI:
intra-abdominal abscess, wound infection), gastroparesis, and hemorrhage. The incidence of
SSI (superficial and deep) is about 35% and seems influenced by the prolonged drainage of
intra-abdominal. For several years, there is a global trend to reduce the use of abdominal
drainage after abdominal surgery. Several randomized clinical trials have shown that
prophylactic drainage does not decrease the incidence of postoperative complications during
elective hepatectomy, colectomy, and cholecystectomy and could increase the number of SSI.
However, the role of prophylactic drainage after PD is so far unclear. In the literature,
three studies have examined the influence of drainage of the abdominal cavity after PD, and
were published at the time this protocol was submitted :
- The study of Conlon et al. (Ann Surg 2001), prospective randomized study comparing no
drainage standard abdominal drainage. The SSI rates in the drained group was 36% versus
16% in the undrained group (NS, but in his critical study methodology).
- The study of Kawai et al. (Ann Surg 2006), non-randomized prospective study comparing
short drainage (D4) drainage standard (D8). The SSI rates in the drained group was 38%
versus 7.7% in the undrained group (significant but non-randomized study involving
patients on two consecutive periods).
- Study Berberat et al. (Büchler) (J Gastrointest Surg 2007), retrospective analysis of a
population of patients with a PD (80%) the results by intention to treat the early
removal of drainage of the abdominal cavity. The SSI rates published in this study is
9.4%.
After acceptance of this protocol by local ethics committee, a forth study was published by
Bassi et al (Bassi C Ann Surg 2010) : it is a randomized controlled study. Patients who
underwent pancreatic resection (including left pancreatic resection) and at low risk of
postoperative pancreatic fistula were randomized on post operative day (POD) 3 to receive
either early (POD 3) or standard drain removal (POD 5 or beyond). The primary end point of
the study was the incidence of pancreatic fistula. This study shows that, in patients with a
low risk of pancreatic fistula after pancreatic resection, intra-abdominal drains can be
safely removed on POD 3 after standard pancreatic resections. A prolonged period of drain
insertion is associated with a higher rate of postoperative complications with increased
hospital stay.
The aim of the present prospective randomized multicenter study is to evaluate the influence
of short drainage (4 days) of the abdominal cavity versus standard drainage (10 to 15 days,
depending on the staff clinical practice) after PD on the rate of SSI.
Materials and Methods: The technique of PD is left at the discretion of the operator as well
as the prescription of analogues of somatostatin. Drainage of the abdominal cavity is made
of one or two round silicone close suction drains or open multichannel silicone drains
placed in the vicinity of the pancreatic and biliary anastomosis. Shall be excluded patients
operated on for chronic pancreatitis and patients who underwent preoperative radiotherapy.
The 3rd postoperative day, a pancreatic fistula is sought clinically, biologically and on
CT-scanner images. In case of pancreatic fistula, the patient is excluded from randomization
and drainage of the abdominal cavity is left in place depending on the different teams'
practice. Patients without fistula are randomized to either drainage removal 4 days after
surgery (D4) or standard drainage.
Analysis and outcomes: The primary endpoint will be the occurrence of surgical site
infection (SSI) at D30, as defined by:
- surface SSI (wound abscess): infection of the skin, subcutaneous tissue or muscle,
above the fascia, located at a surgical incision. The diagnosis is based on at least
one of the following criteria:
- The fluid from the wound or drain located above the fascia is purulent
- A spontaneous dehiscence of the wound
- A positive culture from a closed wound.
- deep SSI (intra-abdominal abscess) infection in operated tissues or in site of
intervention (under the fascia). The diagnosis is based on at least one of the
following criteria:
- The fluid from a drain positioned beneath the fascia is purulent;
- A culture from a closed wound is positive;
- Other signs of infection on direct examination found during a re-operation.
Secondary outcomes will be the length of hospital stay, postoperative complications, with
emphasis on classification IIIa (radiological drainage) and IIIb (re-intervention) of
Clavien (Dindo et al. Ann Surg 2004).
All patients who underwent PD during the study period, especially patients excluded before
randomization will be collected.
Calculating the number of patients needed to reduce SSI rate from 30% (in the group standard
drainage of the abdominal cavity) to 10% (in the short drainage group), with a risk alpha of
0.05 and a risk beta of 0.20 yields 124 patients. Taking into account 10% of patients not
analyzable, the number of patients included in this study is 138 (69 patients in each arm).
Five university hospitals are participating in the study (Amiens, Lille, Caen, and Rouen)
and one general hospital (CH Beauvais). The expected duration of the study is 24 months
(12-14 patients per center per year).
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04085055 -
Fine Needle Biopsy of Solid Pancreatic Mass Lesions
|
N/A | |
Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
Recruiting |
NCT05481476 -
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Completed |
NCT03054987 -
Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction
|
N/A | |
Completed |
NCT02909530 -
Comparison Between Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in EUS-guided FNB of Solid Pancreatic Masses
|
N/A | |
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Completed |
NCT01770405 -
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
|
N/A | |
Terminated |
NCT01515046 -
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
Terminated |
NCT01434459 -
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
|
Phase 1 | |
Completed |
NCT00985777 -
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
|
Phase 1 | |
Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00178763 -
Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer
|
Phase 2 | |
Completed |
NCT00196105 -
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
|
N/A |